Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome

Archives of Gynecology and Obstetrics

Volumn 281, Issue 1, 2010, Pages 35-42

  Kebapcilar, Levent ^a   Taner, Cuneyt Eftal ^b   Kebapcilar, Ayse Gul ^b   Alacacioglu, Ahmet ^a   Sari, Ismail ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Turkey)

^b Aegean Obstetrics and Gynecology Teaching Hospital   (Turkey)

Author keywords

D dimer; Ethinyl estradiol cyproterone acetate; Metformin; Polycystic ovary syndrome; Spironolactone

Indexed keywords

ANDROGEN; D DIMER; DIANE; DIANE NOVA; INSULIN; METFORMIN; PRASTERONE; SPIRONOLACTONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BLOOD CLOTTING; BLOOD EXAMINATION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIET RESTRICTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; FEMALE; HORMONE RESPONSE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LABORATORY TEST; LEUKOCYTE COUNT; METABOLIC PARAMETERS; MONOTHERAPY; NAUSEA; OVARY POLYCYSTIC DISEASE; PARTIAL THROMBOPLASTIN TIME; POLYPHARMACY; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; ALDOSTERONE ANTAGONISTS; BLOOD COAGULATION; CYPROTERONE ACETATE; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HORMONES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; METFORMIN; POLYCYSTIC OVARY SYNDROME; SPIRONOLACTONE; WEIGHT LOSS; YOUNG ADULT;

EID: 71449108402     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-009-1051-y     Document Type: Article

References (28)

1. S Franks 1995 Polycystic ovary syndrome N Engl J Med 333 853 861 10.1056/NEJM199509283331307 10.1056/NEJM199509283331307 1:STN:280: DyaK2MznvF2jug%3D%3D 7651477
2. S von Eckardstein A von Eckardstein HG Bender H Schulte G Assmann 1996 Elevated low-density lipoprotein-cholesterol in women with polycystic ovary syndrome Gynecol Endocrinol 10 311 318 10.3109/09513599609012817 10.3109/09513599609012817
3. GS Conway PM Clark D Wong 1993 Hyperinsulinaemia in the polycystic ovary syndrome confirmed with a specific immunoradiometric assay for insulin Clin Endocrinol (Oxf) 38 219 222 10.1111/j.1365-2265.1993.tb00996.x 10.1111/j.1365-2265.1993.tb00996.x 1:STN:280:DyaK3s7mvFOquw%3D%3D
4. C Meyer BP McGrath J Cameron D Kotsopoulos HJ Teede 2005 Vascular dysfunction and metabolic parameters in polycystic ovary syndrome J Clin Endocrinol Metab 90 4630 4635 10.1210/jc.2004-1487 10.1210/jc.2004-1487 1:CAS:528:DC%2BD2MXnvVWlurk%3D 15870132 (Pubitemid 41159353)
5. Kebapcilar L, Taner CE, Kebapcilar AG, Sari I (2008) High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet [Epub ahead of print]
6. G Derosa A Dangelo PD Ragonesi L Ciccarelli MN Piccinni F Pricolo S Salvadeo L Montagna A Gravina I Ferrari S Galli S Paniga AF Cicero 2006 Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome J Int Med Res 34 545 555 1:CAS:528:DC%2BD28XhtlSntb3P 17133785
7. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome PCOS Hum Reprod 19 41 47 10.1093/humrep/deh098 10.1093/humrep/deh098 (Pubitemid 38072004)
8. L Morin-Papunen I Vauhkonen R Koivunen A Ruokonen H Martikainen JS Tapanainen 2003 Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study J Clin Endocrinol Metab 88 148 156 10.1210/jc.2002-020997 10.1210/jc.2002-020997 1:CAS:528:DC%2BD3sXkvVersQ%3D%3D 12519844 (Pubitemid 36115157)
9. M Luque-Ramírez F Alvarez-Blasco JI Botella-Carretero E Martínez-Bermejo MA Lasunción HF Escobar-Morreale 2007 Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome J Clin Endocrinol Metab 92 2453 2461 10.1210/jc.2007-0282 10.1210/jc.2007-0190 17426085 (Pubitemid 47037342)
10. F Karakurt II Gumus N Bavbek A Kargili C Koca Y Selcoki M Ozbek A Kosar A Akcay 2008 Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome Gynecol Endocrinol 24 491 497 10.1080/09513590802291824 10.1080/09513590802291824 1:CAS:528:DC%2BD1cXht12ltLbN 18958767
11. M Luque-Ramírez C Mendieta-Azcona JM del Rey Sánchez M Matíes HF Escobar-Morreale 2009 Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking Eur J Endocrinol 160 469 480 10.1530/EJE-08-0725 10.1530/EJE-08-0725 19139031
12. N Kiliçli-Camur R Demirtunç C Konuralp A Eskiser Y Başaran 2005 Could mean platelet volume be a predictive marker for acute myocardial infarction? Med Sci Monit 11 CR387 CR392 16049381
13. JA Jakubowski CB Thompson R Vaillancourt, et al. 1983 Arachidonic acid metabolism by platelets of differing size Br J Haematol 53 503 511 10.1111/j.1365-2141.1983.tb02052.x 10.1111/j.1365-2141.1983.tb02052.x 1:CAS:528:DyaL3sXhsVWhsrg%3D 6402003
14. P Moghetti R Castello C Negri F Tosi F Perrone M Caputo E Zanolin M Muggeo 2000 Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation J Clin Endocrinol Metab 85 139 146 10.1210/jc.85.1.139 10.1210/jc.85.1.139 1:CAS:528:DC%2BD3cXjtl2huw%3D%3D 10634377 (Pubitemid 32268804)
15. R Fleming ZE Hopkinson AM Wallace IA Greer N Sattar 2002 Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial J Clin Endocrinol Metab 87 569 574 10.1210/jc.87.2.569 10.1210/jc.87.2.569 1:CAS:528:DC%2BD38XhsVSjurs%3D 11836287 (Pubitemid 34158220)
16. K Elter G Imir F Durmusoglu 2002 Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study Hum Reprod 17 1729 1737 10.1093/humrep/17.7.1729 10.1093/humrep/17.7.1729 1:CAS:528:DC%2BD38Xmt1Glsbw%3D 12093831
17. M Mitkov B Pehlivanov D Terzieva 2005 Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome Eur J Obstet Gynecol Reprod Biol 118 209 213 10.1016/j.ejogrb.2004.06.035 10.1016/j.ejogrb.2004.06.035 1:CAS:528:DC%2BD2MXkvFagtg%3D%3D 15653205 (Pubitemid 40093836)
18. J Wu Y Zhu Y Jiang Y Cao 2008 Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome Gynecol Endocrinol 24 392 398 10.1080/09513590802217027 10.1080/09513590802217027 1:CAS:528: DC%2BD1cXovFWktbg%3D 18608522 (Pubitemid 352032232)
19. R Pasquali A Gambineri B Anconetani V Vicennati D Colitta E Caramelli F Casimirri AM Morselli-Labate 1999 The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestogen treatment Clin Endocrinol (Oxf) 50 517 527 10.1046/j.1365-2265.1999.00701.x 10.1046/j.1365-2265.1999.00701.x 1:CAS:528:DyaK1MXjtVyqtrw%3D (Pubitemid 29193237)
20. A Cagnacci AM Paoletti A Renzi M Orrù M Pilloni GB Melis A Volpe 2003 Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel J Clin Endocrinol Metab 88 3621 3625 10.1210/jc.2003-030328 10.1210/jc.2003-030328 1:CAS:528:DC%2BD3sXmsFOktr0%3D 12915645 (Pubitemid 37034504)
21. D Cibula M Fanta J Vrbikova S Stanicka K Dvorakova M Hill J Skrha J Zivny J Skrenkova 2005 The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients Hum Reprod 20 180 184 10.1093/humrep/deh588 10.1093/humrep/deh588 1:CAS:528:DC%2BD2MXisVSgtw%3D%3D 15576394
22. J Vrbíková S Stanická K Dvoráková M Hill K Vondra B Bendlová L Stárka 2004 Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjunction with peroral cyproterone acetate in women with polycystic ovary syndrome Eur J Endocrinol 150 215 223 10.1530/eje.0.1500215 10.1530/eje.0.1500215 14763920 (Pubitemid 38312814)
23. A Holmang BM Larsson Z Brzezinska P Bjorntorp 1992 Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats Am J Physiol 262 E851 E855 1:STN:280:DyaK38zht1KqtA%3D%3D 1616020
24. J Rincon A Holmang EO Wahlstrom P Lonnroth P Bjorntorp JR Zierath H Wallberg-Henriksson 1996 Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment Diabetes 45 615 621 10.2337/diabetes.45.5.615 10.2337/diabetes.45.5.615 1:CAS:528: DyaK28Xjs1ylsLs%3D 8621012
25. L Moran RJ Norman 2004 Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome Best Pract Res Clin Obstet Gynaecol 18 719 736 10.1016/j.bpobgyn.2004.05.003 10.1016/j.bpobgyn.2004.05.003 1:STN:280:DC%2BD2crit1Wrug%3D%3D 15380143 (Pubitemid 40424607)
26. LJ Moran M Noakes PM Clifton L Tomlinson RJ Norman 2003 Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome J Clin Endocrinol Metab 88 812 819 10.1210/jc.2002-020815 10.1210/jc.2002-020815 1:CAS:528:DC%2BD3sXhtlChtLc%3D 12574218 (Pubitemid 36207827)
27. KM Hoeger 2006 Role of lifestyle modification in the management of polycystic ovary syndrome Best Pract Res Clin Obstet Gynaecol 20 293 310
28. M Mitkov B Pehlivanov D Terzieva 2006 Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome Eur J Obstet Gynecol Reprod Biol 126 93 98 10.1016/j.ejogrb.2005.11.019 10.1016/j.ejogrb.2005.11.019 1:CAS:528:DC%2BD28XksVGjsL0%3D 16360262 (Pubitemid 44294601)